Amicus Therapeutics Inc Sustainability Reports

Amicus Therapeutics is a global biotechnology company focused on discovering, developing, and delivering novel medicines for people living with rare metabolic diseases. Its core products include therapies for Fabry disease and Pompe disease.

Sector: Manufacturing

Country: United States

Exchange: Nasdaq

LEI: 549300MRD1SMUTNBPQ53

FIGI: BBG001SN96V9

12 reports from 2010 to 2024

• Amicus Therapeutics Inc 2024 Annual Report
• Amicus Therapeutics Inc 2023 Annual Report
• Amicus Therapeutics Inc 2023 Environmental, Social, and Governance Report
• Amicus Therapeutics Inc 2022 Annual Report
• Amicus Therapeutics Inc 2022 Environmental, Social, and Governance Report